Related references
Note: Only part of the references are listed.Cdh1-mediated Skp2 degradation by dioscin reprogrammes aerobic glycolysis and inhibits colorectal cancer cells growth
Li Zhou et al.
EBIOMEDICINE (2020)
Clonal MET Amplification as a Determinant of Tyrosine Kinase Inhibitor Resistance in Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer
Gillianne Gy Lai et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
MGMT-activated DUB3 stabilizes MCL1 and drives chemoresistance in ovarian cancer
Xiaowei Wu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)
Novel hybrids of podophyllotoxin and formononetin inhibit the growth, migration and invasion of lung cancer cells
Chengli Yang et al.
BIOORGANIC CHEMISTRY (2019)
Discovery and anticancer evaluation of a formononetin derivative against gastric cancer SGC7901 cells
Jian-Ning Yao et al.
INVESTIGATIONAL NEW DRUGS (2019)
Molecular Comprehension of Mcl-1: From Gene Structure to Cancer Therapy
Viacheslav V. Senichkin et al.
TRENDS IN CELL BIOLOGY (2019)
Focus on Formononetin: Anticancer Potential and Molecular Targets
Samantha Kah Ling Ong et al.
CANCERS (2019)
Formononetin: A Review of Its Anticancer Potentials and Mechanisms
Kai-Ching Tay et al.
FRONTIERS IN PHARMACOLOGY (2019)
Intrinsic Resistance to EGFR-Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small Cell Lung Cancer: Differences and Similarities with Acquired Resistance
Eric Santoni-Rugiu et al.
CANCERS (2019)
Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer
Alessandro Leonetti et al.
BRITISH JOURNAL OF CANCER (2019)
MCL-1 inhibitors ? where are we now (2019)?
Steven Fletcher
EXPERT OPINION ON THERAPEUTIC PATENTS (2019)
Systemic Therapy for Locally Advanced and Metastatic Non-Small Cell Lung Cancer A Review
Kathryn C. Arbour et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2019)
Skp2-mediated ubiquitination and mitochondrial localization of Akt drive tumor growth and chemoresistance to cisplatin
Xinfang Yu et al.
ONCOGENE (2019)
Degradation of MCL-1 by bufalin reverses acquired resistance to osimertinib in EGFR-mutant lung cancer
Fei Cao et al.
TOXICOLOGY AND APPLIED PHARMACOLOGY (2019)
Resistance mechanisms to osimertinib in EGFR-mutated advanced non-small-cell lung cancer: A multicentric retrospective French study
Camille Mehlman et al.
LUNG CANCER (2019)
Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC)
Ana C. Z. Gelatti et al.
LUNG CANCER (2019)
Anti-Colorectal Cancer Mechanisms of Formononetin Identified by Network Pharmacological Approach
Lei Zhang et al.
MEDICAL SCIENCE MONITOR (2019)
Formononetin and metformin act synergistically to inhibit growth of MCF-7 breast cancer cells in vitro
Min Xin et al.
BIOMEDICINE & PHARMACOTHERAPY (2019)
Targeting Mcl-1 and other Bcl-2 family member proteins in cancer therapy
Ryuji Yamaguchi et al.
PHARMACOLOGY & THERAPEUTICS (2019)
Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy
Ferdinandos Skoulidis et al.
NATURE REVIEWS CANCER (2019)
Tyrosine Kinase Inhibitors Increase MCL1 Degradation and in Combination with BCLXL/BCL2 Inhibitors Drive Prostate Cancer Apoptosis
Seiji Arai et al.
CLINICAL CANCER RESEARCH (2018)
Deubiquitinase USP13 dictates MCL1 stability and sensitivity to BH3 mimetic inhibitors
Shengzhe Zhang et al.
NATURE COMMUNICATIONS (2018)
Repression of Noxa by Bmi1 contributes to deguelin-induced apoptosis in non-small cell lung cancer cells
Wei Li et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2018)
MCL-1 inhibition in cancer treatment
Weiguo Xiang et al.
ONCOTARGETS AND THERAPY (2018)
Increased Synthesis of MCL-1 Protein Underlies Initial Survival of EGFR-Mutant Lung Cancer to EGFR Inhibitors and Provides a Novel Drug Target
Kyung-A Song et al.
CLINICAL CANCER RESEARCH (2018)
FBW7 mutations mediate resistance of colorectal cancer to targeted therapies by blocking Mcl-1 degradation
J. Tong et al.
ONCOGENE (2017)
Overcoming Acquired Resistance to AZD9291, A Third-Generation EGFR Inhibitor, through Modulation of MEK/ERK-Dependent Bim and Mcl-1 Degradation
Puyu Shi et al.
CLINICAL CANCER RESEARCH (2017)
Targeting FBW7 as a Strategy to Overcome Resistance to Targeted Therapy in Non-Small Cell Lung Cancer
Mingxiang Ye et al.
CANCER RESEARCH (2017)
Mcl-1 Degradation Is Required for Targeted Therapeutics to Eradicate Colon Cancer Cells
Jingshan Tong et al.
CANCER RESEARCH (2017)
EGFR signaling defines Mcl-1 survival dependency in neuroblastoma
Srilatha Nalluri et al.
CANCER BIOLOGY & THERAPY (2015)
Clinical approaches to treat patients with non-small cell lung cancer and epidermal growth factor receptor tyrosine kinase inhibitor acquired resistance
Alfredo Tartarone et al.
THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE (2015)
3,6,2′,4′,5′-Pentahydroxyflavone, an Orally Bioavailable Multiple Protein Kinase Inhibitor, Overcomes Gefitinib Resistance in Non-small Cell Lung Cancer
Yuqiao Sheng et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2014)
Mcl-1 Mediates TWEAK/Fn14-Induced Non-Small Cell Lung Cancer Survival and Therapeutic Response
Timothy G. Whitsett et al.
MOLECULAR CANCER RESEARCH (2014)
Trim17-mediated ubiquitination and degradation of Mcl-1 initiate apoptosis in neurons
M. M. Magiera et al.
CELL DEATH AND DIFFERENTIATION (2013)
Bcr-Abl ubiquitination and Usp9x inhibition block kinase signaling and promote CML cell apoptosis
Hanshi Sun et al.
BLOOD (2011)
Epidermal growth factor regulates Mcl-1 expression through the MAPK-Elk-1 signalling pathway contributing to cell survival in breast cancer
E. P. Booy et al.
ONCOGENE (2011)
Mcl-1 is a potential therapeutic target in multiple types of cancer
C. Akgul
CELLULAR AND MOLECULAR LIFE SCIENCES (2009)
Degradation of Mcl-1 by β-TrCP mediates glycogen synthase kinase 3-induced tumor suppression and chemosensitization
Qingqing Ding et al.
MOLECULAR AND CELLULAR BIOLOGY (2007)
MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling
Jeffrey A. Engelman et al.
SCIENCE (2007)
Mule/ARF-BP1, a BH3-only E3 ubiquitin ligase, catalyzes the polyubiquitination of Mcl-1 and regulates apoptosis
Q Zhong et al.
CELL (2005)
EGFR mutation and resistance of non-small-cell lung cancer to gefitinib
S Kobayashi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
The Protein Data Bank
HM Berman et al.
NUCLEIC ACIDS RESEARCH (2000)
Share Paper
